ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
ABBOTT LABORATORIES
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026
$104.06−0.83 (-0.79%)
Close on Oct 19, 2026
- Market cap
- $181.37B
- P/E (TTM)
- 33.5
- Dividend yield
- 2.31%
ABBOTT LABORATORIES revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medical Devices | $5.85B | $5.54B | $5.68B | $5.45B | $5.37B | $4.90B | $5.05B | $4.75B | $4.73B | $4.45B | $4.44B | $4.25B | 46.5% | +9.0% |
| Diagnostic Products | $3.09B | $2.18B | $2.46B | $2.25B | $2.17B | $2.05B | $2.52B | $2.41B | $2.20B | $2.21B | $2.53B | $2.45B | 24.6% | +42.3% |
| Nutritional Products | $2.14B | $2.02B | $1.94B | $2.15B | $2.21B | $2.15B | $2.13B | $2.07B | $2.15B | $2.07B | $2.04B | $2.07B | 17.0% | -3.1% |
| Established Pharmaceuticals | $1.50B | $1.43B | $1.38B | $1.51B | $1.38B | $1.26B | $1.27B | $1.41B | $1.29B | $1.23B | $1.22B | $1.37B | 11.9% | +8.4% |
| Operating income | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medical Devices | $1.97B | $1.89B | $1.98B | $1.83B | $1.80B | $1.61B | $1.77B | $1.51B | $1.51B | $1.36B | $1.50B | $1.34B | +9.6% |
| Diagnostic Products | $499.00M | $335.00M | $609.00M | $400.00M | $372.00M | $359.00M | $611.00M | $558.00M | $430.00M | $474.00M | $713.00M | $632.00M | +34.1% |
| Established Pharmaceuticals | $382.00M | $365.00M | $255.00M | $391.00M | $346.00M | $298.00M | $271.00M | $380.00M | $315.00M | $267.00M | $254.00M | $345.00M | +10.4% |
| Nutritional Products | $368.00M | $311.00M | $386.00M | $360.00M | $418.00M | $394.00M | $443.00M | $312.00M | $373.00M | $377.00M | $361.00M | $284.00M | -12.0% |
By product or service
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| International | $7.38B | $6.89B | $7.08B | $7.07B | $6.87B | $6.19B | $6.63B | $6.43B | $6.44B | $6.12B | $6.29B | $6.33B | 58.6% | +7.4% |
| United States | $5.22B | $4.27B | $4.38B | $4.30B | $4.28B | $4.17B | $4.34B | $4.20B | $3.93B | $3.85B | $3.95B | $3.82B | 41.4% | +22.0% |
From the segment and revenue-disaggregation notes of Abbott Laboratories's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.